Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Division of Genomic Medicine, |
RCV001250762 | SCV001425607 | pathogenic | Tuberous sclerosis 2 | 2020-07-10 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001250762 | SCV004632422 | pathogenic | Tuberous sclerosis 2 | 2023-09-14 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 65369). Disruption of this splice site has been observed in individual(s) with tuberculosis sclerosis complex (PMID: 32211034). In at least one individual the variant was observed to be de novo. This variant is not present in population databases (gnomAD no frequency). This sequence change affects an acceptor splice site in intron 37 of the TSC2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in TSC2 are known to be pathogenic (PMID: 10205261, 17304050). |
Tuberous sclerosis database |
RCV000055594 | SCV000083819 | not provided | Tuberous sclerosis syndrome | no assertion provided | curation |